The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The use of machine learning models to predict PFS and OS outcomes from waterfall plots in randomized clinical trials (MAP-OUTCOMES).
 
Khadjah Alshankati
No Relationships to Disclose
 
Aisha Alshibany
No Relationships to Disclose
 
Augustin Toma
No Relationships to Disclose
 
Katherine Lajkosz
No Relationships to Disclose
 
Bo Wang
No Relationships to Disclose
 
Benjamin Haibe-Kains
Stock and Other Ownership Interests - Code Biotherapeutics; IONIQ Sciences
Honoraria - Takeda
Consulting or Advisory Role - Break Through Cancer; CQDM,
Research Funding - Roche
Travel, Accommodations, Expenses - Roche Canada; Takeda
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)